CN1739794A - 一种胸腺素α1的水溶液制剂、其制备方法及应用 - Google Patents
一种胸腺素α1的水溶液制剂、其制备方法及应用 Download PDFInfo
- Publication number
- CN1739794A CN1739794A CN 200510102988 CN200510102988A CN1739794A CN 1739794 A CN1739794 A CN 1739794A CN 200510102988 CN200510102988 CN 200510102988 CN 200510102988 A CN200510102988 A CN 200510102988A CN 1739794 A CN1739794 A CN 1739794A
- Authority
- CN
- China
- Prior art keywords
- thymosin
- preparation
- disodiumedetate
- sodium chloride
- edta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010078233 Thymalfasin Proteins 0.000 title abstract description 13
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 title abstract description 13
- 229960004231 thymalfasin Drugs 0.000 title abstract description 13
- 102400000800 Thymosin alpha-1 Human genes 0.000 title abstract description 11
- 238000000034 method Methods 0.000 title description 5
- 230000008569 process Effects 0.000 title description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 47
- 239000003814 drug Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000012856 packing Methods 0.000 claims abstract description 8
- 206010019799 Hepatitis viral Diseases 0.000 claims abstract description 6
- 201000001862 viral hepatitis Diseases 0.000 claims abstract description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 4
- -1 etc. Substances 0.000 claims abstract description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 2
- 229930195725 Mannitol Natural products 0.000 claims abstract 2
- 239000000594 mannitol Substances 0.000 claims abstract 2
- 235000010355 mannitol Nutrition 0.000 claims abstract 2
- 108010046075 Thymosin Proteins 0.000 claims description 48
- 102000007501 Thymosin Human genes 0.000 claims description 48
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims description 48
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 34
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 17
- 239000008363 phosphate buffer Substances 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 claims 1
- 150000001860 citric acid derivatives Chemical class 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 230000001900 immune effect Effects 0.000 abstract 2
- 238000013329 compounding Methods 0.000 abstract 1
- 229920000151 polyglycol Polymers 0.000 abstract 1
- 239000010695 polyglycol Substances 0.000 abstract 1
- 230000002992 thymic effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 28
- 239000000047 product Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000011835 investigation Methods 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 4
- 229960001627 lamivudine Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical class [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101710142246 External core antigen Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011082 depyrogenation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 229940098312 lamivudine 100 mg Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002773 nucleotide Chemical group 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
批号 | 时间(天) | 考察项目 | |||||
外观性状 | pH值 | 澄明度 | 澄清度与颜色 | 有关物质(%) | 含量(%) | ||
01 | 0 | 无色澄明 | 6.81 | 符合规定 | 澄清无色 | 0.18 | 99.01 |
5 | 无色澄明 | 5.42 | 符合规定 | 澄清无色 | 0.78 | 83.49 | |
10 | 无色澄明 | 5.10 | 符合规定 | 澄清无色 | 1.44 | 79.23 |
批号 | 时间(天) | 考察项目 | |||||
外观性状 | pH值 | 澄明度 | 溶液的澄清度与颜色 | 有关物质(%) | 含量(%) | ||
01 | 0 | 无色澄明 | 6.84 | 符合规定 | 澄清无色 | 0.20 | 99.14 |
5 | 无色澄明 | 6.32 | 符合规定 | 澄清无色 | 3.85 | 80.56 | |
10 | 无色澄明 | 6.11 | 符合规定 | 澄清无色 | 5.02 | 77.2 |
批号 | 时间(天) | 考察项目 | |||||
外观性状 | pH值 | 澄明度 | 溶液的澄清度与颜色 | 有关物质(%) | 含量(%) | ||
01 | 0 | 无色澄明 | 6.83 | 符合规定 | 澄清无色 | 0.19 | 99.27 |
5 | 无色澄明 | 6.37 | 符合规定 | 澄清无色 | 0.64 | 93.10 | |
10 | 无色澄明 | 6.25 | 符合规定 | 澄清无色 | 1.39 | 92.44 |
批号 | 时间(天) | 考察项目 | |||||
外观性状 | pH值 | 澄明度 | 溶液的澄清度与颜色 | 有关物质(%) | 含量(%) | ||
01 | 0 | 无色澄明 | 6.82 | 符合规定 | 澄清无色 | 0.23 | 99.58 |
5 | 无色澄明 | 6.79 | 符合规定 | 澄清无色 | 0.45 | 99.17 | |
10 | 无色澄明 | 6.77 | 符合规定 | 澄清无色 | 1.01 | 98.63 |
批号 | 月 | 考察项目 | ||||||
外观性状 | pH | 澄明度 | 有关物质(%) | 内毒素 | 无菌 | 含量(%) | ||
02 | 0 | 无色澄明 | 6.80 | 符合规定 | 0.22 | 符合规定 | 符合规定 | 100.00 |
1 | 无色澄明 | 6.04 | 符合规定 | 5.86 | - | - | 94.92 | |
2 | 溶液浑浊 | 5.86 | 溶液浑浊 | 9.20 | - | - | 87.41 | |
3 | 溶液浑浊 | 5.59 | 溶液浑浊 | 14.55 | - | - | 81.52 | |
6 | 溶液浑浊 | 4.97 | 溶液浑浊 | 20.64 | - | - | 72.48 |
批号 | 月 | 考察项目 | |||||||
外观性状 | 澄清度与颜色 | pH值 | 澄明度 | 有关物质(%) | 内毒素 | 无菌 | 含量(%) | ||
02 | 0 | 无色澄明 | 澄清无色 | 6.78 | 符合规定 | 0.21 | 符合规定 | 符合规定 | 99.85 |
3 | 无色澄明 | 澄清无色 | 6.76 | 符合规定 | 0.28 | 符合规定 | 符合规定 | 99.74 | |
6 | 无色澄明 | 澄清无色 | 6.74 | 符合规定 | 0.30 | 符合规定 | 符合规定 | 99.70 | |
03 | 0 | 无色澄明 | 澄清无色 | 6.82 | 符合规定 | 0.23 | 符合规定 | 符合规定 | 99.57 |
3 | 无色澄明 | 澄清无色 | 6.77 | 符合规定 | 0.31 | 符合规定 | 符合规定 | 99.46 | |
6 | 无色澄明 | 澄清无色 | 6.75 | 符合规定 | 0.35 | 符合规定 | 符合规定 | 99.21 |
成结数/100淋巴细胞 | 平均成结率(%) | |
阴性对照 | 38.2±4.7 | 38.2 |
01号样品 | 54.6±3.6* | 54.6 |
冻干粉针对照(日达仙) | 55.1±3.1* | 55.1 |
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101029883A CN100342909C (zh) | 2005-05-11 | 2005-09-16 | 一种胸腺素α1的水溶液制剂、其制备方法及应用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510069082.6 | 2005-05-11 | ||
CN200510069082 | 2005-05-11 | ||
CNB2005101029883A CN100342909C (zh) | 2005-05-11 | 2005-09-16 | 一种胸腺素α1的水溶液制剂、其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1739794A true CN1739794A (zh) | 2006-03-01 |
CN100342909C CN100342909C (zh) | 2007-10-17 |
Family
ID=36092416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101029883A Active CN100342909C (zh) | 2005-05-11 | 2005-09-16 | 一种胸腺素α1的水溶液制剂、其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100342909C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102233130A (zh) * | 2010-04-28 | 2011-11-09 | 江苏豪森药业股份有限公司 | 稳定的含有胸腺肽1衍生物的药物制剂 |
CN104511013A (zh) * | 2013-09-26 | 2015-04-15 | 长春海悦药业有限公司 | 一种含有胸腺肽的药物组合物及其制剂 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101361962B (zh) * | 2008-10-07 | 2012-05-23 | 厦门大学 | 胸腺素α1的一种新用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1216056B (it) * | 1988-03-11 | 1990-02-22 | Sclavo Spa | Composizioni farmaceutiche contenenti timosina alfa 1. |
NZ262634A (en) * | 1993-02-23 | 1997-02-24 | Genentech Inc | Stabilizing polypeptides against degradation by organic solvents by admixing the peptide with trehalose or mannitol |
PT1491208E (pt) * | 1999-10-04 | 2010-05-12 | Novartis Vaccines & Diagnostic | Composições farmacêuticas contendo polipéptido líquidas estabilizadas |
CA2396503A1 (en) * | 1999-12-14 | 2001-06-21 | Jeffrey W. Steaffens | Stabilizing diluent for polypeptides and antigens |
SI21258A (sl) * | 2002-07-17 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol |
-
2005
- 2005-09-16 CN CNB2005101029883A patent/CN100342909C/zh active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102233130A (zh) * | 2010-04-28 | 2011-11-09 | 江苏豪森药业股份有限公司 | 稳定的含有胸腺肽1衍生物的药物制剂 |
CN102233130B (zh) * | 2010-04-28 | 2013-05-01 | 江苏豪森药业股份有限公司 | 稳定的含有胸腺肽1衍生物的药物制剂 |
CN104511013A (zh) * | 2013-09-26 | 2015-04-15 | 长春海悦药业有限公司 | 一种含有胸腺肽的药物组合物及其制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN100342909C (zh) | 2007-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100337684C (zh) | 一种胸腺五肽的水溶液制剂、其制备方法及应用 | |
CN1809376A (zh) | 装在药物容器中的稳定的液体蛋白质制剂 | |
CN1662252A (zh) | 稳定性提高的酸性胰岛素制剂 | |
CN1120458A (zh) | 生理活性肽组合物 | |
CN101683519B (zh) | 一种胸腺肽α1与胸腺五肽的组合物及其制备方法 | |
CN100342909C (zh) | 一种胸腺素α1的水溶液制剂、其制备方法及应用 | |
CN102048712A (zh) | 一种稳定的含有变应原的膜剂药物组合物及其制备方法 | |
CN1259041C (zh) | 注射用盐酸溴己新无菌冻干制剂及其制备方法 | |
CN1429558A (zh) | 甘露聚糖肽注射液及其制备方法和使用方法 | |
CN1748785A (zh) | 一种还原型谷胱甘肽的水溶液制剂、其制备方法及应用 | |
CN100336557C (zh) | 一种生长抑素的水溶液制剂、其制备方法及应用 | |
Rebagay et al. | Residues in antibiotic preparations, i: scanning electron microscopic studies of surface topography | |
CN100435843C (zh) | 一种胸腺五肽与干扰素的组合物 | |
CN111978394B (zh) | 用于covid-19患者特异性免疫疗法的多克隆制剂的制备方法 | |
CN1748790A (zh) | 一种天门冬酰胺酶注射液、其制备方法及应用 | |
CN1247259C (zh) | 重组人干扰素α喷雾剂 | |
CN1522746A (zh) | 一种红景天药物制剂及其制备方法与用途 | |
CN1802172A (zh) | 用于自身免疫性病症的治疗组合物 | |
CN1138572A (zh) | 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途 | |
CN113082203B (zh) | 一种免疫抑制剂单克隆抗体的液体制剂 | |
CN108210457B (zh) | 胶原蛋白肽的药物应用、葫芦素口服胶束及其制备方法 | |
RU2380405C2 (ru) | Способ получения рекомбинантного альфа 16-интерферона человека и фармацевтическая композиция для лечения вирусных заболеваний на основе рекомбинантного альфа 16-интерферона человека | |
Anderson et al. | Biological activity of recombinant interleukin-2 in intravenous admixtures containing antibiotic, morphine sulfate, or total parenteral nutrient solution | |
CN1679914A (zh) | 还原型谷胱甘肽和依布硒啉的组合药物 | |
CN104998262B (zh) | Dpp4抑制剂在防治辐射诱导骨髓抑制药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING SL LISHENG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING SHUANGLU PHARMACEUTICAL CO., LTD. Effective date: 20130607 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100041 SHIJINGSHAN, BEIJING TO: 102200 CHANGPING, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130607 Address after: 102200 No. 2 li Xiang Road, Changping District science and Technology Park, Beijing Patentee after: Beijing SL Lisheng Medical Technology Co.,Ltd. Address before: 100041, No. 9 middle Garden Road, Badachu hi tech park, Beijing, Shijingshan District Patentee before: BEIJING SL PHARMACEUTICAL Co.,Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Beijing SL Lisheng Medical Technology Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice |
Addressee: Liu Chengdong Document name: Review Business Specific Letter |
|
DD01 | Delivery of document by public notice |